Elan to Buy Back $1 Billion of Stock After Tysabri Sale

Elan Corp. plans to buy back $1 billion of stock, equal to 16 percent of the company’s market value, after selling its stake in the Tysabri multiple sclerosis drug to Biogen Idec Inc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.